共查询到20条相似文献,搜索用时 15 毫秒
1.
From random screening of our compound libraries, we identified a hit compound with an IC50 of 27 microM against hepatitis C viral NS5B RNA-dependent RNA polymerase. By using a parallel synthetic strategy, a series of its derivatives were synthesized. From their anti-HCV activity screening, compounds with single digital 3.8 micromolar activity were obtained. 相似文献
2.
Hutchinson DK Rosenberg T Klein LL Bosse TD Larson DP He W Jiang WW Kati WM Kohlbrenner WE Liu Y Masse SV Middleton T Molla A Montgomery DA Beno DW Stewart KD Stoll VS Kempf DJ 《Bioorganic & medicinal chemistry letters》2008,18(14):3887-3890
4,4-Dialkyl-1-hydroxy-3-oxo-3.4-dihydronaphthalene-3-yl benzothiadiazine derivatives were synthesized and evaluated as inhibitors of genotypes 1a and 1b HCV NS5B polymerase. A number of these compounds exhibited potent activity against genotypes 1a and 1b HCV polymerase in both enzymatic and cell culture activities. A representative compound also showed favorable pharmacokinetics in the rat. 相似文献
3.
Zheng X Hudyma TW Martin SW Bergstrom C Ding M He F Romine J Poss MA Kadow JF Chang CH Wan J Witmer MR Morin P Camac DM Sheriff S Beno BR Rigat KL Wang YK Fridell R Lemm J Qiu D Liu M Voss S Pelosi L Roberts SB Gao M Knipe J Gentles RG 《Bioorganic & medicinal chemistry letters》2011,21(10):2925-2929
Herein, we present initial SAR studies on a series of bridged 2-arylindole-based NS5B inhibitors. The introduction of bridging elements between the indole N1 and the ortho-position of the 2-aryl moiety resulted in conformationally constrained heterocycles that possess multiple additional vectors for further exploration. The binding mode and pharmacokinetic (PK) properties of select examples, including: 13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[2,1-d][1,4]benzodiazepine-10-carboxylic acid (7) (IC50 = 0.07 μM, %F = 18), are reported. 相似文献
4.
A. Chris Krueger John T. Randolph David A. DeGoey Pamela L. Donner Charles A. Flentge Douglas K. Hutchinson Dachun Liu Christopher E. Motter Todd W. Rockway Rolf Wagner David W.A. Beno Gennadiy Koev Hock B. Lim Jill M. Beyer Rubina Mondal Yaya Liu Warren M. Kati Kenton L. Longenecker Clarence J. Maring 《Bioorganic & medicinal chemistry letters》2013,23(12):3487-3490
The synthesis and structure–activity relationships of a novel aryl uracil series which contains a fused 5,6-bicyclic ring unit for HCV NS5B inhibition is described. Several analogs display replicon cell culture potencies in the low nanomolar range along with excellent rat pharmacokinetic values. 相似文献
5.
《Bioorganic & medicinal chemistry》2016,24(9):2146-2157
Hepatitis C virus (HCV) infection is highly persistent and presents an unmet medical need requiring more effective treatment options. This has spurred intensive efforts to discover novel anti-HCV agents. The RNA-dependent RNA polymerase (RdRp), NS5B of HCV, constitutes a selective target for drug discovery due to its absence in human cells; also, it is the centerpiece for viral replication. Here, we synthesized novel pyrrole, pyrrolo[2,3-d]pyrimidine and pyrrolo[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives. The non-toxic doses of these compounds on Huh 7.5 cell line were determined and their antiviral activity against HCVcc genotype 4a was examined. Compounds 7j, 7f, 5c, 12i and 12f showed significant anti HCV activity. The percent of reduction for the non-toxic doses of 7j, 7f, 5c, 12i and 12f were 90%, 76.7 ± 5.8%, 73.3 ± 5.8%, 70% and 63.3 ± 5.8%, respectively. The activity of these compounds was interpreted by molecular docking against HCV NS5B polymerase enzyme. 相似文献
6.
Gentles RG Ding M Zheng X Chupak L Poss MA Beno BR Pelosi L Liu M Lemm J Wang YK Roberts S Gao M Kadow J 《Bioorganic & medicinal chemistry letters》2011,21(10):3142-3147
Described herein is the initial optimization of (+/−) N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamide (1), a hit discovered in a high throughput screen run against the NS5B polymerase enzyme of the hepatitis C virus. This effort resulted in the identification of (S)-N-sec-butyl-6-((R)-3-(4-(trifluoromethoxy)benzylcarbamoyl)-4-(4-(trifluoromethoxy)phenylsulfonyl)piperazin-1-yl)pyridazine-3-carboxamide (2), that displayed potent replicon activities against HCV genotypes 1b and 1a (EC50 1b/1a = 7/89 nM). 相似文献
7.
Hutchinson DK Flentge CA Donner PL Wagner R Maring CJ Kati WM Liu Y Masse SV Middleton T Mo H Montgomery D Jiang WW Koev G Beno DW Stewart KD Stoll VS Molla A Kempf DJ 《Bioorganic & medicinal chemistry letters》2011,21(6):1876-1879
A series of quinoline derivatives was synthesized as potential bioisosteric replacements for the benzothiadiazine moiety of earlier Hepatitis C NS5B polymerase inhibitors. Several of these compounds exhibited potent activity in enzymatic and replicon assays. 相似文献
8.
Prasanthi Polamreddy Premkumar Arumugam Raghu Bheemanati Poornima Esram Manoj Kumar Mahto 《Journal of biomolecular structure & dynamics》2020,38(5):1448-1466
AbstractNonstructural protein 5B (NS5B), the RNA-dependent RNA polymerase of Hepatitis C Virus (HCV), plays a key role in viral amplification and is an attractive and most explored target for discovery of new therapeutic agents for Hepatitis C. Though safe and effective, NS5B inhibitors were launched in 2013 (Sovaldi) and 2014 (Harvoni, Viekira Pak), the high price tags of these medications limit their use among poor people in developing countries. Hence, still there exists a need for cost-effective and short duration anti-HCV agents especially those targeting niche patient population who were non-respondent to earlier therapies or with comorbid conditions. The present study describes the discovery of novel non-nucleoside (NNI) inhibitors of NS5B using a series of rational drug design techniques such as virtual screening, scaffold matching and molecular docking. 2D and 3D structure based virtual screening technique identified 300 hit compounds. Top 20 hits were screened out from identified hits using molecular docking technique. Four molecules, that are representative of 20 hits were evaluated for binding affinity under in vitro conditions using surface plasmon resonance-based assay and the results emphasized that compound with CoCoCo ID: 412075 could exhibit good binding response toward NS5B and could be a potential candidate as NS5B inhibitor.Communicated by Ramaswamy H. Sarma 相似文献
9.
Jackson RW LaPorte MG Herbertz T Draper TL Gaboury JA Rippin SR Patel R Chunduru SK Benetatos CA Young DC Burns CJ Condon SM 《Bioorganic & medicinal chemistry letters》2011,21(11):3227-3231
We describe the structure-activity relationship of the C7-position of pyrano[3,4-b]indole-based inhibitors of HCV NS5B polymerase. Further exploration of the allosteric binding site led to the discovery of the significantly more potent compounds 13 and 14. 相似文献
10.
Barbara Zhizhen Zheng Stanley V. DAndrea Umesh Hanumegowda Jay O. Knipe Kathy Mosure Xiaoliang Zhuo Julie A. Lemm Mengping Liu Karen L. Rigat Ying-Kai Wang Hua Fang Chris Poronsky Jingfang Cutrone Dauh-Rurng Wu Pirama Nayagam Arunachalam T.J. Balapragalathan Arunachalam Arumugam Arvind Mathur John F. Kadow 《Bioorganic & medicinal chemistry letters》2017,27(15):3294-3300
The synthesis, structure-activity relationship (SAR) data, and further optimization of the metabolic stability and pharmacokinetic (PK) properties for a previously disclosed class of cyclopropyl-fused indolobenzazepine HCV NS5B polymerase inhibitors are described. These efforts led to the discovery of BMS-961955 as a viable contingency backup to beclabuvir which was recently approved in Japan for the treatment of HCV as part of a three drug, single pill combination marketed as XimencyTM. 相似文献
11.
Timothy A. Stammers René Coulombe Jean Rancourt Bounkham Thavonekham Gulrez Fazal Sylvie Goulet Araz Jakalian Dominic Wernic Youla Tsantrizos Marc-André Poupart Michael Bös Ginette McKercher Louise Thauvette George Kukolj Pierre L. Beaulieu 《Bioorganic & medicinal chemistry letters》2013,23(9):2585-2589
A novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors were derived from a fragment-based approach using information from X-ray crystallographic analysis of NS5B-inhibitor complexes and iterative rounds of parallel synthesis. Structure-based drug design strategies led to the discovery of potent sub-micromolar inhibitors 11a–c and 12a–c from a weak-binding fragment-like structure 1 as a starting point. 相似文献
12.
Moyi Liu Qiaoling Xu Su Guo Ruixi Zuo Yue Hong Yong Luo Yingxiu Li Ping Gong Yajing Liu 《Bioorganic & medicinal chemistry》2018,26(9):2621-2631
The hepatitis C virus (HCV) NS5B polymerase is an attractive target for the development of novel and selective inhibitors of HCV replication. In this paper, the design, synthesis, and preliminary SAR studies of novel inhibitors of HCV NS5B polymerase based on the structure of tegobuvir have been described. The efforts to optimize the antiviral potency and reduce the treatment side effects with respect to genotype 1b resulted in the discovery of compound 3, which exhibited an EC50 of 1.163?nM and a CC50 >200?nM in a cell-based HCV replicon system assay. Additionally, testing for inhibition of the hERG channel showed a marked improvement over tegobuvir and the pharmacokinetic properties of compound 3 indicated that it was worthy of further investigation as a non-nucleoside inhibitor of HCV NS5B polymerase. 相似文献
13.
I. Novel HCV NS5B polymerase inhibitors: discovery of indole 2-carboxylic acids with C3-heterocycles
Anilkumar GN Lesburg CA Selyutin O Rosenblum SB Zeng Q Jiang Y Chan TY Pu H Vaccaro H Wang L Bennett F Chen KX Duca J Gavalas S Huang Y Pinto P Sannigrahi M Velazquez F Venkatraman S Vibulbhan B Agrawal S Butkiewicz N Feld B Ferrari E He Z Jiang CK Palermo RE McMonagle P Huang HC Shih NY Njoroge G Kozlowski JA 《Bioorganic & medicinal chemistry letters》2011,21(18):5336-5341
SAR development of indole-based palm site inhibitors of HCV NS5B polymerase exemplified by initial indole lead 1 (NS5B IC(50)=0.9 μM, replicon EC(50)>100 μM) is described. Structure-based drug design led to the incorporation of novel heterocyclic moieties at the indole C3-position which formed a bidentate interaction with the protein backbone. SAR development resulted in leads 7q (NS5B IC(50)=0.032 μM, replicon EC(50)=1.4 μM) and 7r (NS5B IC(50)=0.017 μM, replicon EC(50)=0.3 μM) with improved enzyme and replicon activity. 相似文献
14.
Antonysamy SS Aubol B Blaney J Browner MF Giannetti AM Harris SF Hébert N Hendle J Hopkins S Jefferson E Kissinger C Leveque V Marciano D McGee E Nájera I Nolan B Tomimoto M Torres E Wright T 《Bioorganic & medicinal chemistry letters》2008,18(9):2990-2995
Non-nucleoside inhibitors of HCV NS5b RNA polymerase were discovered by a fragment-based lead discovery approach, beginning with crystallographic fragment screening. The NS5b binding affinity and biochemical activity of fragment hits and inhibitors was determined by surface plasmon resonance (Biacore) and an enzyme inhibition assay, respectively. Crystallographic fragment screening hits with 1–10 mM binding affinity (KD) were iteratively optimized to give leads with 200 nM biochemical activity and low μM cellular activity in a Replicon assay. 相似文献
15.
Kumar DV Rai R Brameld KA Somoza JR Rajagopalan R Janc JW Xia YM Ton TL Shaghafi MB Hu H Lehoux I To N Young WB Green MJ 《Bioorganic & medicinal chemistry letters》2011,21(1):82-87
Hepatitis C virus (HCV) infection is treated with a combination of peginterferon alfa-2a/b and ribavirin. To address the limitations of this therapy, numerous small molecule agents are in development, which act by directly affecting key steps in the viral life-cycle. Herein we describe our discovery of quinolone derivatives, novel small-molecules that inhibit NS5b polymerase, a key enzyme of the viral life-cycle. A crystal structure of a quinoline analog bound to NS5B reveals that this class of compounds binds to allosteric site-II (non-nucleoside inhibitor-site 2, NNI-2) of this protein. 相似文献
16.
《Bioorganic & medicinal chemistry letters》2019,29(24):126104
Hepatitis C virus (HCV) NS5B polymerase is a prime target for the development of direct-acting antiviral drugs for the treatment of chronic HCV infection. Several novel and potent HCV NS5B non-nucleoside inhibitors with unique tetracyclic bezonfuran-based structures were prepared and evaluated. Similar to clinical developmental compound MK-8876, N-linked (compounds 1 and 2) and C-linked (compounds 3 and 4) tetracyclic structures maintained broad spectrum anti-replicon potency profiles and demonstrated moderate to excellent oral bioavailability and pharmacokinetic parameters across the three preclinical animal species. To better understand the importance of tetracyclic structures related to pan genotypic potency profiles especially against clinically relevant GT1a variants, the teracycles with different ring size were prepared and in vitro evaluations suggested compounds with six number ring have better overall potency profiles. 相似文献
17.
Gentles RG Sheriff S Beno BR Wan C Kish K Ding M Zheng X Chupak L Poss MA Witmer MR Morin P Wang YK Rigat K Lemm J Voss S Liu M Pelosi L Roberts SB Gao M Kadow JF 《Bioorganic & medicinal chemistry letters》2011,21(8):2212-2215
Structure based rationales for the activities of potent N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamide inhibitors of the hepatitis C viral polymerase are described herein. These compounds bind to the hepatitis C virus non-structural protein 5B (NS5B), and co-crystal structures of select examples from this series with NS5B are reported. Comparison of co-crystal structures of a potent analog with both NS5B genotype 1a and genotype 1b provides a possible explanation for the genotype-selectivity observed with this compound class and suggests opportunities for the further optimization of the series. 相似文献
18.
Bhargav A. Patel Ramalingam Krishnan Nikhil Khadtare K.R. Gurukumar Amartya Basu Payal Arora Aaditya Bhatt Maulik R. Patel Dibyendu Dana Sanjai Kumar Neerja Kaushik-Basu Tanaji T. Talele 《Bioorganic & medicinal chemistry》2013,21(11):3262-3271
Hepatitis C virus (HCV) NS5B polymerase is a key target for anti-HCV therapeutics development. Herein, we report the synthesis and in vitro evaluation of anti-NS5B polymerase activity of a molecular hybrid of our previously reported lead compounds 1 (IC50 = 7.7 μM) and 2 (IC50 = 10.6 μM) as represented by hybrid compound 27 (IC50 = 6.7 μM). We have explored the optimal substituents on the terminal phenyl ring of the 3-phenoxybenzylidene moiety in 27, by generating a set of six analogs. This resulted in the identification of compound 34 with an IC50 of 2.6 μM. To probe the role of stereochemistry towards the observed biological activity, we synthesized and evaluated the d-isomers 41 (IC50 = 19.3 μM) and 45 (IC50 = 5.4 μM) as enantiomers of the l-isomers 27 and 34, respectively. The binding site of compounds 32 and 34 was mapped to palm pocket-I (PP-I) of NS5B. The docking models of 34 and 45 within the PP-I of NS5B were investigated to envisage the molecular mechanism of inhibition. 相似文献
19.
Kyle Parcella Andrew Nickel Brett R. Beno Steven Sheriff Changhong Wan Ying-Kai Wang Susan B. Roberts Nicholas A. Meanwell John F. Kadow 《Bioorganic & medicinal chemistry letters》2017,27(2):295-298
Alkoxyanthranilic acid derivatives have been identified to inhibit HCV NS5B polymerase, binding in an allosteric site located at the convergence of the palm and thumb regions. Information from co-crystal structures guided the structural design strategy. Ultimately, two independent structural modifications led to a similar shift in binding mode that when combined led to a synergistic improvement in potency and the identification of inhibitors with sub-micromolar HCV NS5B binding potency. 相似文献
20.
Xiaoyan Zhang Nanjing Zhang Guangming Chen Anthony Turpoff Hongyu Ren James Takasugi Christie Morrill Jin Zhu Chunshi Li William Lennox Steven Paget Yalei Liu Neil Almstead F. George Njoroge Zhengxian Gu Takashi Komatsu Valerie Clausen Christine Espiritu Gary M. Karp 《Bioorganic & medicinal chemistry letters》2013,23(13):3947-3953
A novel series of 6-(indol-2-yl)pyridine-3-sulfonamides was prepared and evaluated for their ability to inhibit HCV RNA replication in the HCV replicon cell culture assay. Preliminary optimization of this series furnished compounds with low nanomolar potency against the HCV genotype 1b replicon. Among these, compound 8c has identified as a potent HCV replicon inhibitor (EC50 = 4 nM) with a selectivity index with respect to cellular GAPDH of more than 2500. Further, compound 8c had a good pharmacokinetic profile in rats with an IV half-life of 6 h and oral bioavailability (F) of 62%. Selection of HCV replicon resistance identified an amino acid substitution in HCV NS4B that confers resistance to these compounds. These compounds hold promise as a new chemotype with anti-HCV activity mediated through an underexploited viral target. 相似文献